Affinage

IL10RA

Interleukin-10 receptor subunit alpha · UniProt Q13651

Length
578 aa
Mass
63.0 kDa
Annotated
2026-06-10
79 papers in source corpus 19 papers cited in narrative 19 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

IL10RA encodes the ligand-binding alpha subunit of the IL-10 receptor that transduces anti-inflammatory IL-10 signals through the JAK/STAT3 axis to restrain inflammation (PMID:12802285, PMID:27268052, PMID:37071310). Upon ligand engagement, specific cytoplasmic phosphotyrosines (Tyr446 and Tyr496) are required for receptor function and recruit downstream effectors, with serine substitution at these positions abolishing signaling (PMID:12802285), and the receptor acts upstream of JAK2/STAT3 to drive STAT3 phosphorylation (PMID:27268052). Functionally, IL-10Rα-dependent signaling enforces anti-inflammatory feedback: its loss derepresses pro-inflammatory cytokine/chemokine secretion and abrogates IL-10/SOCS3 induction during infection (PMID:37071310), and in myeloid cells it mediates IL-10 suppression of TLR-induced IL-12 (PMID:22685028). Loss-of-function changes in IL10RA—a missense variant (p.Tyr91Cys) that disrupts plasma-membrane localization and a synonymous splice-disrupting variant (p.T179T) causing exon skipping—each abolish IL-10-induced STAT3 phosphorylation in patient cells, establishing IL10RA defects as a cause of receptor signaling failure (PMID:30462267, PMID:27177777, PMID:26822028). Receptor abundance is set by transcriptional and enhancer-level control: BCL6 represses surface IL-10Rα via the JAK2 promoter (PMID:27268052), type I/III interferons upregulate surface IL-10Rα to amplify STAT3 responses (PMID:22685028), and a super-enhancer SNP (rs4936415) tunes expression through NF-κB1 binding (PMID:39844988). In cancer, aberrant IL-10Rα upregulation rewires STAT3 signaling to drive crizotinib resistance in ALCL by bypassing NPM1-ALK (PMID:32573700), and IL-10Rα-driven STAT3 activity promotes tumor-cell metabolism and proliferation (PMID:39892560), M2-like tumor-associated macrophage polarization (PMID:39215060), and stromal IDO induction with T-cell suppression (PMID:39592739).

Mechanistic history

Synthesis pass · year-by-year structured walk · 10 steps
  1. 2003 High

    Established which cytoplasmic determinants of IL-10Rα are required for signal transduction, defining how the receptor engages downstream effectors.

    Evidence In vitro phosphopeptide co-IP, serine-substitution mutagenesis, and confocal imaging of GFP fusions in cell-free signaling assays

    PMID:12802285

    Open questions at the time
    • Did not place these phosphotyrosines within the full JAK1/TYK2-STAT3 cascade
    • Identity and generality of the IL-10E1 effector across cell types not resolved
  2. 2006 Medium

    Tested whether IL-10Rα proximal signaling is intact in autoimmune disease, distinguishing receptor-level defects from downstream transcriptional dysregulation.

    Evidence Flow cytometry, Western blot kinetics for JAK1/TYK2/STAT1/STAT3, and cDNA microarray of IL-10-stimulated SLE patient PBMCs

    PMID:17062437

    Open questions at the time
    • Mechanism of aberrant gene-expression regulation downstream of normal phosphorylation not identified
    • Correlative patient comparison without causal manipulation
  3. 2012 Medium

    Showed that receptor abundance is a tunable control point, with interferons priming IL-10Rα surface levels to amplify anti-inflammatory output.

    Evidence IFN priming followed by IL-10 stimulation with surface-receptor flow cytometry, pSTAT3 Western blot, and TLR-induced IL-12 ELISA in primary human myeloid cells

    PMID:22685028

    Open questions at the time
    • Transcriptional mechanism of IFN-driven IL-10Rα upregulation not defined
    • Single-lab primary cell study
  4. 2016 High

    Identified transcriptional repression of receptor/kinase expression by BCL6 and a converging autophagy-suppressive role, refining how IL-10Rα output is set and what it controls.

    Evidence Conditional BCL6-KO with ChIP-seq and receptor blockade (lymphoma); pharmacological IL-10R/AKT/mTOR/STAT3 inhibition with autophagy readouts in fibroblasts

    PMID:26962683 PMID:27268052

    Open questions at the time
    • Direct biochemical link between IL-10Rα engagement and AKT-mTOR activation not resolved
    • Generality of BCL6-IL-10Rα axis beyond lymphoma cells unknown
  5. 2016 Medium

    Defined a disease-causing splicing mechanism, showing a synonymous coding variant abolishes receptor signaling in patients with very-early-onset intestinal inflammation.

    Evidence Exome/Sanger sequencing, RT-PCR demonstrating exon skipping, and STAT3 phosphorylation assays in patient PBMCs (two independent reports)

    PMID:26822028 PMID:27177777

    Open questions at the time
    • Quantitative residual receptor function not measured
    • No in vivo or organoid rescue of the splicing defect
  6. 2019 Medium

    Demonstrated that a missense variant disrupts receptor trafficking, linking structural instability to failed surface localization and signaling loss.

    Evidence Surface-expression flow cytometry, confocal imaging of GFP-fused mutants, structural modeling, and STAT3 phosphorylation in patient PBMCs

    PMID:30462267

    Open questions at the time
    • Trafficking/degradation route of the mislocalized mutant not defined
    • Structural disruption inferred computationally, not solved experimentally
  7. 2020 High

    Revealed that pathological IL-10Rα upregulation rewires STAT3 to bypass oncogenic kinase dependence, driving targeted-therapy resistance.

    Evidence Genome-wide CRISPR activation and knockout screens in ALCL lines plus RNA-seq of crizotinib-relapsed patient tumors

    PMID:32573700

    Open questions at the time
    • Upstream trigger of aberrant IL-10Rα induction in resistant tumors not defined
    • Whether ligand-independent or IL-10-driven signaling sustains resistance unclear
  8. 2024 Medium

    Extended IL-10Rα function to stromal immunosuppression, showing receptor expression is required for IDO induction and T-cell suppression in the tumor microenvironment.

    Evidence shRNA IL10RA knockdown in primary MSCs with STAT3, IDO expression/activity, and PDAC organoid killing readouts; BM-MSC/T-cell co-culture with IL-10 neutralization

    PMID:25326368 PMID:39592739

    Open questions at the time
    • Direct STAT3-to-IDO transcriptional link not biochemically mapped
    • In vitro co-culture systems without in vivo confirmation
  9. 2024 Medium

    Established IL-10Rα as a regulatory node setting receptor-expression states and myeloid behavior across tissue and tumor contexts.

    Evidence Super-enhancer SNP analysis (ChIP, luciferase, EMSA) for NF-κB1-dependent expression; IL-10R blockade and shRNA in myeloid/DC models in vitro and in vivo; type I IFN cross-regulation in Ifnar1-/- colitis

    PMID:29190678 PMID:37033926 PMID:39215060 PMID:39844988

    Open questions at the time
    • Cell-type-specific transcriptional control of IL-10Rα incompletely mapped
    • Causal contribution of receptor-expression hysteresis to in vivo outcomes inferred indirectly
  10. 2025 Medium

    Probed dynamic and context-dependent regulation of IL-10R expression states governing tumor immune evasion, metabolism, and circadian antiviral protection.

    Evidence Engineered Salmonella tumor models, IL-10Rα overexpression/knockdown with Seahorse metabolic flux, and circadian IL-10R blockade in influenza models (one preprint)

    PMID:39892560 PMID:40037354 PMID:bio_10.1101_2025.03.03.641134

    Open questions at the time
    • Molecular basis of IL-10R expression hysteresis not defined
    • Circadian regulation evidence is a single preprint lacking molecular dissection of IL-10Rα

Open questions

Synthesis pass · forward-looking unresolved questions
  • How IL-10Rα proximal phosphotyrosine signaling is mechanistically coupled to both STAT3 and the AKT-mTOR branch, and what governs the switch-like control of receptor surface abundance across cell types, remains unresolved.
  • No structural model of the assembled ligand-bound receptor complex in the corpus
  • Direct biochemical bridge from IL-10Rα to AKT-mTOR not established
  • Unified mechanism linking receptor-expression state to functional output not defined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060089 molecular transducer activity 3 GO:0048018 receptor ligand activity 1
Localization
GO:0005886 plasma membrane 4
Pathway
R-HSA-162582 Signal Transduction 3 R-HSA-168256 Immune System 3
Partners
IL10JAK2STAT3
Complex memberships
IL-10 receptor

Evidence

Reading pass · 19 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2003 Two specific tyrosine residues in the cytoplasmic domain of IL-10Rα (Tyr446 and Tyr496) are required for receptor function and for phosphorylation/activation of the downstream effector IL-10E1. Phosphorylated peptides encompassing these residues co-precipitated IL-10E1 and blocked ligand-dependent IL-10E1 phosphorylation, whereas serine substitutions at these positions abolished signaling. IL-10 triggers nuclear translocation of IL-10E1, dependent on these phosphotyrosines. In vitro phosphopeptide immunoprecipitation, site-directed mutagenesis (serine substitution), confocal microscopy of GFP-fusion proteins, cell-free signaling assays Oncogene High 12802285
2016 IL-10 inhibits starvation-induced autophagy in hypertrophic scar fibroblasts via two converging pathways downstream of IL-10Rα: (1) IL-10Rα-mediated activation of STAT3, and (2) direct activation of the AKT-mTOR pathway; mTOR-p70S6K is the convergence point. Blocking IL-10Rα with a specific inhibitor (IL10RB) abolished both STAT3 phosphorylation and AKT-mTOR activation and restored autophagy. Pharmacological inhibition of IL-10R, AKT, mTOR, and STAT3; Western blot for p-AKT, p-STAT3, p-mTOR; transmission electron microscopy for autophagy; dose-response assays in primary fibroblasts Cell death & disease Medium 26962683
2016 BCL6 directly represses the JAK2 promoter (confirmed by ChIP-seq) and suppresses surface IL-10Rα expression; loss of BCL6 leads to elevated IL-10Rα surface levels, increased JAK2 mRNA/protein, and STAT3 phosphorylation. Blockade of IL-10Rα in BCL6-deficient Burkitt lymphoma cells repressed STAT3 phosphorylation, placing IL-10Rα upstream of JAK2/STAT3 in this pathway. Synthetic lethal screen, conditional BCL6-deficient cell line, surface IL-10Rα measurement, IL-10Rα blockade + STAT3 phosphorylation readout, ChIP-seq The Journal of biological chemistry High 27268052
2012 Type I interferons (IFN-α, IFN-β) and the type III interferon IL-29 upregulate IL-10R1 (IL-10Rα) surface expression on human monocytes and macrophages, increasing STAT3 phosphorylation in response to IL-10 and thereby enhancing IL-10-mediated suppression of TLR-induced IL-12p70 production. Flow cytometry for IL-10R1 surface expression, Western blot for pSTAT3, IFN priming followed by IL-10 stimulation and TLR-induced IL-12 measurement by ELISA in primary human monocytes/macrophages European journal of immunology Medium 22685028
2020 Aberrant upregulation of IL-10Rα expression in ALCL cells rewires STAT3 signaling, bypassing the normally required phosphorylation by NPM1-ALK, and thereby drives resistance to ALK inhibition by crizotinib. This was identified through genome-wide CRISPR activation and knockout screens combined with RNA-seq from relapsed patient tumors. Genome-wide CRISPR activation and knockout screens in ALCL cell lines; RNA sequencing of ALK inhibitor-relapsed patient tumors; functional validation of IL-10Rα-driven STAT3 signaling Blood High 32573700
2019 The IL-10Rα missense variant p.Tyr91Cys fails to properly localize to the plasma membrane, likely due to disruption of a hydrophobic core structure around Tyr91, causing structural instability. Patient PBMCs with this variant showed defective STAT3 activation upon IL-10 stimulation. Flow cytometry for surface IL-10Rα expression, confocal microscopy of GFP-fused mutant proteins, computational structural modeling, STAT3 phosphorylation assay in patient PBMCs Inflammatory bowel diseases Medium 30462267
2006 IL-10Rα on SLE patient PBMCs signals normally through JAK-1, TYK-2, STAT-1, and STAT-3 phosphorylation, but IL-10R-dependent gene expression (cytokines, apoptosis, intracellular signaling) is aberrantly regulated in SLE patients compared to controls. Flow cytometry for IL-10R expression, Western blot for JAK-1/TYK-2/STAT-1/STAT-3 phosphorylation, cDNA microarray of 242 genes after IL-10 stimulation of patient PBMCs Scandinavian journal of rheumatology Medium 17062437
2024 IL-10Rα expression on mesenchymal stem cells (MSCs) is required for IDO induction in co-culture with T cells: IL-10RA knockdown in MSCs significantly reduced IDO RNA, protein, and enzymatic activity, as well as STAT3 phosphorylation. This decreased T cell suppression and restored T cell cytotoxic killing of PDAC organoids. IL-10RA shRNA knockdown in primary MSCs, co-culture with T cells, STAT3 phosphorylation measurement, IDO activity assay, PDAC organoid killing assay British journal of cancer Medium 39592739
2025 IL-10Rα overexpression in non-small cell lung cancer cells promotes proliferation by enhancing glycolysis and fatty acid oxidation (FAO) via activation of the STAT3 signaling pathway. STAT3 inhibition blocked the FAO increase and cell proliferation induced by IL-10Rα overexpression. IL-10RA overexpression and knockdown in NSCLC cell lines, cell proliferation assays, Seahorse metabolic flux assays for glycolysis and FAO, STAT3 inhibitor rescue experiments Pulmonary pharmacology & therapeutics Medium 39892560
2024 IL-10/IL-10R/STAT3 axis signaling mediates M2-like polarization of tumor-associated macrophages in multiple myeloma bone marrow. Blocking IL-10Rα with a monoclonal antibody prevented M2 polarization and TAM-induced MM proliferation and drug resistance in vitro and in vivo. IL-10R monoclonal antibody blockade, STAT3 PROTAC degrader, 3D co-culture in vitro, patient BM samples, mouse xenograft models; M2/M1 macrophage phenotyping, MM proliferation and drug-sensitivity assays Leukemia Medium 39215060
2015 BM-MSCs upregulate IL-10 secretion and the expression of its receptor CD210 (IL-10Rα) on co-cultured T cells, creating an autocrine/paracrine loop favoring expansion of IL-10-producing T cells. IL-10 neutralization restored T cell proliferation, demonstrating that the IL-10/IL-10Rα axis is functionally required for MSC-mediated T cell immunosuppression. Co-culture of T cells with BM-MSCs, IL-10 ELISA, flow cytometry for CD210/IL-10Rα surface expression, cell-trace proliferation assay, IL-10 neutralization rescue experiment, qPCR Stem cell reviews and reports Medium 25326368
2025 The hysteretic nonlinearity of IL-10R expression drives tumor-infiltrated immune cells into an IL-10Rhi state. Bacteria (engineered Salmonella) leverage elevated IL-10R expression to enhance IL-10 production by tumor-associated macrophages and enable phagocytosis evasion by tumor-associated neutrophils, while coincidently expanding exhausted tumor-resident CD8+ T cells. Engineered Salmonella enterica in murine tumor models, flow cytometry for IL-10R expression states, functional assays for macrophage IL-10 production and neutrophil phagocytosis, human sample analysis Cell Medium 40037354
2023 IL-10RA knockout in bovine mammary epithelial cells (IL10RAKO MAC-T) infected with MAP led to greater secretion of pro-inflammatory cytokines (TNF-α, IL-6, IFN-γ, CCL3, CCL4, CXCL8, CXCL10) and loss of anti-inflammatory IL-10 and SOCS3 induction compared to wild-type cells, demonstrating that IL-10Rα mediates anti-inflammatory feedback during MAP infection. Additionally, miRNA responses (miR-133b, miR-92a, miR-184) induced by MAP infection in WT cells were absent in IL10RAKO cells. CRISPR-generated IL10RA knockout MAC-T cell line, MAP infection, multiplex immunoassay for cytokines/chemokines, qPCR for inflammatory genes and miRNAs In vitro cellular & developmental biology. Animal Medium 37071310
2016 A synonymous variant in IL10RA (p.T179T, c.537G>A) located before the 5' splice donor site causes exon skipping and out-of-frame fusion of exons 3 and 5, resulting in altered STAT3 phosphorylation in IL-10-induced PBMCs from patients with this mutation. Whole-exome and Sanger sequencing, RT-PCR to demonstrate aberrant splicing, STAT3 phosphorylation assay in patient PBMCs Journal of Crohn's & colitis Medium 27177777
2016 A novel exonic mutation in IL10RA (c.537G>A, p.T179T) causes aberrant splicing resulting in loss of IL-10 receptor signaling (demonstrated by lack of STAT3 phosphorylation in patient PBMCs upon IL-10 stimulation). Sanger sequencing, RT-PCR for splice analysis, STAT3 phosphorylation assay in patient PBMCs BMC gastroenterology Medium 26822028
2025 IL-10R expression in the lung exhibits diurnal rhythmicity (circadian expression of Il10ra); blocking IL-10 signaling abrogated time-of-day-specific protection against influenza A virus, increasing immunopathology (enhanced lymphocyte infiltration, global immune activation). NK cell depletion suppressed IL-10 levels, suggesting NK cells regulate IL-10 signaling in the lung. IL-10R blockade in mice at different circadian times, transcriptomic analysis, NK cell depletion, BALF cytokine measurement, survival assays bioRxivpreprint Low bio_10.1101_2025.03.03.641134
2024 A non-coding SNP (rs4936415) in an IL10RA super-enhancer region regulates IL-10Rα expression: the protective G-allele promotes enhancer activity, while the risk C-allele specifically binds NF-κB1, which also promotes enhancer activity. BD patients show significantly lower serum IL-10Rα levels. This was established by ChIP, luciferase reporter assay, and EMSA. Chromatin immunoprecipitation (ChIP), luciferase gene-reporter assay, electrophoretic mobility shift assay (EMSA), ELISA for serum IL-10Rα levels, GWAS post-annotation bioinformatics Heliyon Medium 39844988
2017 IL-10R+ colonic macrophages and dendritic cells are more abundant in mice lacking type I IFN signaling (Ifnar1-/-) during Salmonella colitis; blockade of IL-10R in Ifnar1-/- mice increased susceptibility to S. typhimurium colitis, demonstrating a cross-regulatory interaction in which type I IFN restrains immunoregulatory IL-10R-expressing myeloid cells and that their IL-10 signaling is protective. Ifnar1-/- mouse model, IL-10R blockade (anti-IL-10R mAb), flow cytometry for macrophage/DC subsets and IL-10R expression, survival and colitis severity scoring PloS one Medium 29190678
2023 Downregulation of IL-10R expression in dendritic cells (via lentiviral shRNA) enhances their ability to activate anti-tumor immune responses in vitro and, combined with HES-MTX nanoconjugate, leads to greatest tumor growth inhibition in MC38 murine colon carcinoma in vivo, with decreased suppressor cell infiltration and increased effector cell infiltration in tumors. Lentiviral shRNA knockdown of IL-10R in DCs, in vivo tumor model (MC38), flow cytometry of tumor-infiltrating immune cells, ELISA, tumor volume monitoring Frontiers in immunology Medium 37033926

Source papers

Stage 0 corpus · 79 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2013 IL-10R polymorphisms are associated with very-early-onset ulcerative colitis. Inflammatory bowel diseases 194 22550014
2000 Comparative quantification of IL-1beta, IL-10, IL-10r, TNFalpha and IL-7 mRNA levels in UV-irradiated human skin in vivo. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 110 10939619
2013 A Mendelian predisposition to B-cell lymphoma caused by IL-10R deficiency. Blood 109 24089328
2016 IL10 inhibits starvation-induced autophagy in hypertrophic scar fibroblasts via cross talk between the IL10-IL10R-STAT3 and IL10-AKT-mTOR pathways. Cell death & disease 68 26962683
2025 Bacterial immunotherapy leveraging IL-10R hysteresis for both phagocytosis evasion and tumor immunity revitalization. Cell 55 40037354
2012 IL-10R blockade during chronic schistosomiasis mansoni results in the loss of B cells from the liver and the development of severe pulmonary disease. PLoS pathogens 53 22291593
2022 The clinical, molecular, and therapeutic features of patients with IL10/IL10R deficiency: a systematic review. Clinical and experimental immunology 44 35481870
2007 Influence of IL-10RA and IL-22 polymorphisms on outcome of hepatitis C virus infection. Liver international : official journal of the International Association for the Study of the Liver 43 17845543
2024 IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myeloma. Leukemia 39 39215060
2012 Type I and III interferons enhance IL-10R expression on human monocytes and macrophages, resulting in IL-10-mediated suppression of TLR-induced IL-12. European journal of immunology 37 22685028
2016 Novel exonic mutation inducing aberrant splicing in the IL10RA gene and resulting in infantile-onset inflammatory bowel disease: a case report. BMC gastroenterology 36 26822028
2020 IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma. Blood 35 32573700
2015 Bone Marrow Mesenchymal Stromal Cells Induce Proliferative, Cytokinic and Molecular Changes During the T Cell Response: The Importance of the IL-10/CD210 Axis. Stem cell reviews and reports 33 25326368
2021 Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells. Blood cancer journal 31 34392305
2016 A Synonymous Variant in IL10RA Affects RNA Splicing in Paediatric Patients with Refractory Inflammatory Bowel Disease. Journal of Crohn's & colitis 31 27177777
2018 Umbilical Cord Blood Transplantation Corrects Very Early-Onset Inflammatory Bowel Disease in Chinese Patients With IL10RA-Associated Immune Deficiency. Inflammatory bowel diseases 29 29788474
2015 Association study of functional polymorphisms in interleukins and interleukin receptors genes: IL1A, IL1B, IL1RN, IL6, IL6R, IL10, IL10RA and TGFB1 in schizophrenia in Polish population. Schizophrenia research 29 26481614
2012 Graphene oxide absorbed anti-IL10R antibodies enhance LPS induced immune responses in vitro and in vivo. Immunology letters 28 23064239
2016 Early Diagnosis and Hematopoietic Stem Cell Transplantation for IL10R Deficiency Leading to Very Early-Onset Inflammatory Bowel Disease Are Essential in Familial Cases. Case reports in immunology 22 27699073
2010 Interleukin 10 receptor alpha subunit (IL-10RA) gene polymorphism and IL-10 serum levels in Egyptian atopic patients. Journal of investigational allergology & clinical immunology 21 20232770
2018 The expression of IL10RA in colorectal cancer and its correlation with the proliferation index and the clinical stage of the disease. Cytokine 19 29730384
2017 Expression of CD19+CD24highCD38high B cells, IL‑10 and IL‑10R in peripheral blood from patients with systemic lupus erythematosus. Molecular medicine reports 19 28901380
2013 Genetic evidence of regulatory gene variants of the STAT6, IL10R and FOXP3 locus as a susceptibility factor in uncomplicated malaria and parasitaemia in Congolese children. Malaria journal 19 23297791
2005 Polymorphism of the mouse gene for the interleukin 10 receptor alpha chain (Il10ra) and its association with the autoimmune phenotype. Immunogenetics 19 16160826
2013 TLR4, IL10RA, and NOD2 mutation in paediatric Crohn's disease patients: an association with Mycobacterium avium subspecies paratuberculosis and TLR4 and IL10RA expression. Medical microbiology and immunology 18 23455702
2020 Intestinal dysbiosis in pediatric Crohn's disease patients with IL10RA mutations. World journal of gastroenterology 17 32587451
2018 Computational Protein Phenotype Characterization of IL10RA Mutations Causative to Early Onset Inflammatory Bowel Disease (IBD). Frontiers in genetics 14 29755507
2016 Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma. The Journal of biological chemistry 14 27268052
2011 Combined promoter haplotypes of the IL10R genes are associated with protection against severe malaria in Gabonese children. Immunogenetics 14 21814839
2019 Current concepts in pediatric inflammatory bowel disease; IL10/IL10R colitis as a model disease. International journal of pediatrics & adolescent medicine 13 31304220
2001 Semiautomated and simultaneous analysis of the interleukin-10 gene microsatellites IL-10G and IL-10R by fluorescence-based polymerase chain reaction reveals significant differences in allele distributions between Caucasians (Germany) and Africans (Gabon). European cytokine network 13 11566635
2023 Combined therapy with methotrexate nanoconjugate and dendritic cells with downregulated IL-10R expression modulates the tumor microenvironment and enhances the systemic anti-tumor immune response in MC38 murine colon carcinoma. Frontiers in immunology 12 37033926
2018 A strategy of targeting B10 cell by CD19scFv-IL10R for tumor therapy. Biochemical and biophysical research communications 12 30404730
2018 IL-10RA Mutation as a Risk Factor of Severe Influenza-Associated Encephalopathy: A Case Report. Pediatrics 11 29724880
2006 Expression and function of IL-10R in mononuclear cells from patients with systemic lupus erythematosus. Scandinavian journal of rheumatology 11 17062437
2024 A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells. Cellular oncology (Dordrecht, Netherlands) 10 39008193
1999 Polymorphisms within the interleukin-10 receptor cDNA gene (IL10R) in Japanese patients with systemic lupus erythematosus. Rheumatology (Oxford, England) 10 10556270
2025 Mechanistic insights curcumin's anti-inflammatory in pancreatic cancer: experimental and computational evidence implicating IL1B interference via IL10RA upregulation and NLRP3/TLR3 downregulation. Frontiers in cell and developmental biology 8 40535567
2023 Impact of Mycobacterium avium subsp. paratuberculosis infection on bovine IL10RA knockout mammary epithelial (MAC-T) cells. In vitro cellular & developmental biology. Animal 8 37071310
2020 Association of variants in IL1B, TLR9, TREM1, IL10RA, and CD3G and Native American ancestry on malaria susceptibility in Colombian populations. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 8 33316430
2003 IL-10 signaling via IL-10E1 is dependent on tyrosine phosphorylation in the IL-10R alpha chain in human primary prostate cancer cell lines. Oncogene 8 12802285
2016 Genetic variant of IL-10RA and susceptibility to rheumatoid arthritis in a Chinese population. Clinical rheumatology 7 27796662
2024 IL-10RA governor the expression of IDO in the instruction of lymphocyte immunity. British journal of cancer 6 39592739
2021 Characterization of novel and large fragment deletions in exon 1 of the IL10RA gene in Chinese children with very early onset inflammatory bowel diseases. BMC gastroenterology 6 33849446
2017 Type I interferon signaling restrains IL-10R+ colonic macrophages and dendritic cells and leads to more severe Salmonella colitis. PloS one 6 29190678
2012 Genetic polymorphisms in IL10RA and TNF modify the association between blood transfusion and risk of non-Hodgkin lymphoma. American journal of hematology 6 22649007
2023 Association of IL10RA, IL10RB, and IL22RA Polymorphisms/Haplotypes with Susceptibility to and Clinical Manifestations of SLE. International journal of molecular sciences 5 37511050
2021 Establishment of human induced pluripotent stem cell line (SDQLCHi040-A) from a patient with Infantile-onset inflammatory bowel disease carrying a homozygous mutation in IL10RA gene. Stem cell research 5 34530396
2019 Novel Compound Heterozygote Mutation in IL10RA in a Patient With Very Early-Onset Inflammatory Bowel Disease. Inflammatory bowel diseases 5 30462267
2019 Neonatal Crohn's disease with Oral ulcer as the first symptom caused by a compound heterozygote mutation in IL-10RA: a case report. Hereditas 5 31889944
2018 Compound heterozygous mutations in IL10RA combined with a complement factor properdin mutation in infantile-onset inflammatory bowel disease. European journal of gastroenterology & hepatology 5 30199474
2017 Determination of normal expression patterns of CD86, CD210a, CD261, CD262, CD264, CD358, and CD361 in peripheral blood and bone marrow cells by flow cytometry. Immunology letters 5 29274771
2016 Family-based association study of interleukin 10 (IL10) and interleukin 10 receptor alpha (IL10RA) functional polymorphisms in schizophrenia in Polish population. Journal of neuroimmunology 5 27397081
2024 Successful Allogeneic Hematopoietic Cell Transplantation for Patients with IL10RA Deficiency in Japan. Journal of clinical immunology 4 39264505
2021 Case Report: A Novel Compound Heterozygous Mutation in IL-10RA in a Chinese Child With Very Early-Onset Inflammatory Bowel Disease. Frontiers in pediatrics 4 34113591
2025 IL-10RA promotes lung cancer cell proliferation by increasing fatty acid oxidation via STAT3 signaling pathway. Pulmonary pharmacology & therapeutics 3 39892560
2025 Successful Use of Anakinra in a Patient with IL-10R Beta Deficiency: A Case Report. Pediatric allergy, immunology, and pulmonology 3 39950990
2025 Treatment of IL-10RA deficiency of pediatric patients with very early onset inflammatory bowel disease by allogeneic haematopoietic stem cell transplantation. Scientific reports 3 40113867
2020 Fecal Microbial Signatures Are Associated With Engraftment Failure Following Umbilical Cord Blood Transplantation in Pediatric Crohn's Disease Patients With IL10RA Deficiency. Frontiers in pharmacology 3 33162889
2019 An integration-free iPSC line (SDQLCHi012-A) derived from a patient with inflammatory bowel disease- 28 carrying compound heterozygote mutations in IL10RA gene. Stem cell research 3 31648101
2021 Unconventional WD40 domain-dependent role of ATG16L1 in the regulation of IL10R (interleukin 10 receptor) endocytosis, trafficking and signaling. Autophagy 2 34251955
2018 Association of IL-10 and IL-10RA single nucleotide polymorphisms with the responsiveness to HBV vaccination in Chinese infants of HBsAg(+)/HBeAg(-) mothers: a nested case-control study. BMJ open 2 30498038
2017 Data on IL-10R neutralization-induced chronic colitis in Lipocalin 2 deficient mice on BALB/c background. Data in brief 2 28349107
2025 Pitfalls in the diagnosis of apparent homozygous mutations: two cases of IL10RA deficiency inflammatory bowel disease and a literature review. Orphanet journal of rare diseases 1 40611267
2025 Lymphocytes and monocytes undergo swift suppression of IL-10R, IL-6R, and IL-2Rβγ signaling under high concentrations of different cytokines. bioRxiv : the preprint server for biology 1 40654786
2024 Characteristics of the gut microbiota and the effect of Bifidobacterium in very early-onset inflammatory bowel disease patients with IL10RA mutations. Frontiers in microbiology 1 39687875
2023 MiR-4763-3p accelerates lipopolysaccharide-induced cardiomyocyte apoptosis and inflammatory response by targeting IL10RA. Cytotechnology 1 38495290
2022 [Clinical characteristics and identification of a novel IL10RA variant in association with very early-onset inflammatory bowel disease]. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 1 36082572
2019 Phenotypic characteristics and clinical manifestations of inflammatory bowel disease in infants and children under 2 years of age in Liaoning Province, China: five of six infants with IL-10R mutations. Paediatrics and international child health 1 30900524
2014 Content of IL-10 and CD4+CD210+ cells in mice with adjuvant arthritis before and after treatment with cryopreserved placental cells. Bulletin of experimental biology and medicine 1 25257438
2026 IL10R Inhibition Induces Neutrophil Tumoricidal Activity. Cancer immunology research 0 41499552
2026 Exploring genotype-phenotype correlations in three pediatric patients with IL10RA variants and very early-onset inflammatory bowel disease. BMC gastroenterology 0 41606474
2026 [Clinical Analysis of Allogeneic Hematopoietic Stem Cell Transplantation for Very Early-Onset Inflammatory Bowel Disease Caused by IL-10RA Mutation]. Zhongguo shi yan xue ye xue za zhi 0 41846353
2026 Thalidomide-mediated immunomodulation in a patient with IL-10RA deficiency-associated very early-onset inflammatory bowel disease. Frontiers in immunology 0 42064076
2025 Identification of Novel IL-10RA Variant in Infantile-Onset Inflammatory Bowel Disease: A Case Series With Preliminary Genotype-Phenotype Correlation From Two Chinese Families. Case reports in medicine 0 41425514
2024 Correlation and Prediction of IL-10Ra and DKK-4 Plasma Levels in Patients with Calcium Oxalate Urolithiasis. Clinical laboratory 0 39506574
2024 Genetic predisposition to Behcet's disease mediated by a IL10RA enhancer polymorphism. Heliyon 0 39844988
2023 [Analysis of a child with Very early onset inflammatory bowel disease due to compound heterozygous variants of IL10RA and DUOX2 genes]. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 0 37906150
2022 ATG16L1 WD40 domain-dependent IL10R (interleukin 10 receptor) signaling is insensitive to the T300A Crohn disease risk polymorphism. Autophagy 0 35311452

Missed literature

Know a paper Affinage missed for IL10RA? Flag it for the maintainers and the community.

No submissions yet.